Ayala Pharmaceuticals Inc (ADXS)

[ubmmg]

They keep wasting precious resources, spreading themselves very thin. It's deja vu all over again: unable to focus on programs that are furthest ahead and have clinical data. All others should be put on hold until the cash issue is resolved if ever.

KB:" And in addition, I’d point out that, we have another asset that that’s early in development in the vet space, where we are utilizing the optimized construct that we’ve developed for HOT and NEO, where we put multiple antigens in there. And now we – we’re able to do that in the vet space like we did successfully with our HER2 construct that’s on the market today.

And so, we think there’s a nice monetization opportunity, very intriguing opportunity in the vet space to monetize through partnerships. We obviously have a partner today that’s getting acquired, so that would be the first place we would go to, to have a conversation. But just to point out that there are many different ways that we can monetize the science as we already have monetized HER2, both for vet use and for use in humans for pediatric osteosarcoma. And we’ll continue to look for ways to continue to monetize the platform, such as through the vet applications that I mentioned."